>>Signaling Pathways>> TGF-β / Smad Signaling>> PKC>>Hypocrellin A

Hypocrellin A

Catalog No.GC36282

자연적으로 발생하는 PKC 억제제인 하이포크렐린 A는 항종양, 항바이러스, 항박테리아, 항바이러스 활성과 같은 많은 생물학적 및 약리학적 특성을 가지고 있습니다.

Products are for research use only. Not for human use. We do not sell to patients.

Hypocrellin A Chemical Structure

Cas No.: 77029-83-5

Size 가격 재고 수량
5 mg
US$135.00
재고 있음
10 mg
US$216.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Hypocrellin A, a naturally occurring PKC inhibitor, has many biological and pharmacological properties, such as antitumour, antiviral, antibacterial, and antileishmanial activities. Hypocrellin A is a promising photosensitizer for anticancer photodynamic therapy (PDT)[1][2][3][4]. PKC[1]

[1]. Dang L, et al. Effects of hypocrellin A on expression of vascular endothelial growth factor and endothelin-1 in human umbilical endothelial cells. Am J Chin Med. 2007;35(4):713-23. [2]. Ma YJ, et al. Enhanced Production of Hypocrellin A in Submerged Cultures of Shiraia bambusicola by Red Light. Photochem Photobiol. 2019 May;95(3):812-822. [3]. Fehr MJ, et al. Roles of oxygen and photoinduced acidification in the light-dependent antiviral activity of hypocrellin A. Biochemistry. 1995 Dec 5;34(48):15845-8. [4]. Ma G, et al. Antimicrobial and antileishmanial activities of hypocrellins A and B. Antimicrob Agents Chemother. 2004 Nov;48(11):4450-2.

리뷰

Review for Hypocrellin A

Average Rating: 5 ★★★★★ (Based on Reviews and 31 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Hypocrellin A

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.